EP Wealth Advisors LLC acquired a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,977 shares of the medical research company's stock, valued at approximately $1,080,000.
Other large investors also recently made changes to their positions in the company. Rakuten Securities Inc. bought a new stake in Natera during the 2nd quarter worth about $35,000. Ieq Capital LLC bought a new position in shares of Natera in the second quarter worth about $40,419,000. Robinhood Asset Management LLC bought a new position in shares of Natera in the second quarter worth about $11,177,000. Callan Family Office LLC acquired a new position in shares of Natera during the second quarter worth approximately $972,000. Finally, Keebeck Wealth Management bought a new stake in shares of Natera during the second quarter valued at approximately $2,237,000. Institutional investors own 99.90% of the company's stock.
Insider Transactions at Natera
In related news, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares in the company, valued at approximately $34,264,866.02. This trade represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $267.99, for a total value of $79,057.05. Following the transaction, the insider directly owned 183,774 shares of the company's stock, valued at approximately $49,249,594.26. This trade represents a 0.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is currently owned by company insiders.
Natera Stock Performance
Shares of Natera stock opened at $332.03 on Monday. Natera, Inc. has a 12 month low of $157.43 and a 12 month high of $333.56. The company has a market capitalization of $47.86 billion, a PE ratio of -244.14 and a beta of 1.51. The stock's fifty day simple moving average is $274.24 and its 200 day simple moving average is $229.38.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter last year, the firm posted ($0.74) earnings per share. Natera's revenue was up 37.7% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.02 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a research report on Friday, July 17th. Barclays reiterated an "overweight" rating and issued a $340.00 price objective on shares of Natera in a research report on Friday, August 7th. Robert W. Baird set a $348.00 target price on Natera in a research note on Friday, August 7th. Wall Street Zen lowered Natera from a "buy" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, Wolfe Research started coverage on Natera in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $260.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Natera currently has an average rating of "Moderate Buy" and an average price target of $319.38.
Read Our Latest Stock Analysis on Natera
Natera Profile
(
Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
